Cargando…

Biomarkers for Early Detection, Prognosis, and Therapeutics of Esophageal Cancers

Esophageal cancer (EC) is the deadliest cancer worldwide, with a 92% annual mortality rate per incidence. Esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) are the two major types of ECs, with EAC having one of the worst prognoses in oncology. Limited screening techniques...

Descripción completa

Detalles Bibliográficos
Autores principales: Rai, Vikrant, Abdo, Joe, Agrawal, Devendra K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9968115/
https://www.ncbi.nlm.nih.gov/pubmed/36834728
http://dx.doi.org/10.3390/ijms24043316
_version_ 1784897434259816448
author Rai, Vikrant
Abdo, Joe
Agrawal, Devendra K.
author_facet Rai, Vikrant
Abdo, Joe
Agrawal, Devendra K.
author_sort Rai, Vikrant
collection PubMed
description Esophageal cancer (EC) is the deadliest cancer worldwide, with a 92% annual mortality rate per incidence. Esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) are the two major types of ECs, with EAC having one of the worst prognoses in oncology. Limited screening techniques and a lack of molecular analysis of diseased tissues have led to late-stage presentation and very low survival durations. The five-year survival rate of EC is less than 20%. Thus, early diagnosis of EC may prolong survival and improve clinical outcomes. Cellular and molecular biomarkers are used for diagnosis. At present, esophageal biopsy during upper endoscopy and histopathological analysis is the standard screening modality for both ESCC and EAC. However, this is an invasive method that fails to yield a molecular profile of the diseased compartment. To decrease the invasiveness of the procedures for diagnosis, researchers are proposing non-invasive biomarkers for early diagnosis and point-of-care screening options. Liquid biopsy involves the collection of body fluids (blood, urine, and saliva) non-invasively or with minimal invasiveness. In this review, we have critically discussed various biomarkers and specimen retrieval techniques for ESCC and EAC.
format Online
Article
Text
id pubmed-9968115
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99681152023-02-27 Biomarkers for Early Detection, Prognosis, and Therapeutics of Esophageal Cancers Rai, Vikrant Abdo, Joe Agrawal, Devendra K. Int J Mol Sci Review Esophageal cancer (EC) is the deadliest cancer worldwide, with a 92% annual mortality rate per incidence. Esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) are the two major types of ECs, with EAC having one of the worst prognoses in oncology. Limited screening techniques and a lack of molecular analysis of diseased tissues have led to late-stage presentation and very low survival durations. The five-year survival rate of EC is less than 20%. Thus, early diagnosis of EC may prolong survival and improve clinical outcomes. Cellular and molecular biomarkers are used for diagnosis. At present, esophageal biopsy during upper endoscopy and histopathological analysis is the standard screening modality for both ESCC and EAC. However, this is an invasive method that fails to yield a molecular profile of the diseased compartment. To decrease the invasiveness of the procedures for diagnosis, researchers are proposing non-invasive biomarkers for early diagnosis and point-of-care screening options. Liquid biopsy involves the collection of body fluids (blood, urine, and saliva) non-invasively or with minimal invasiveness. In this review, we have critically discussed various biomarkers and specimen retrieval techniques for ESCC and EAC. MDPI 2023-02-07 /pmc/articles/PMC9968115/ /pubmed/36834728 http://dx.doi.org/10.3390/ijms24043316 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Rai, Vikrant
Abdo, Joe
Agrawal, Devendra K.
Biomarkers for Early Detection, Prognosis, and Therapeutics of Esophageal Cancers
title Biomarkers for Early Detection, Prognosis, and Therapeutics of Esophageal Cancers
title_full Biomarkers for Early Detection, Prognosis, and Therapeutics of Esophageal Cancers
title_fullStr Biomarkers for Early Detection, Prognosis, and Therapeutics of Esophageal Cancers
title_full_unstemmed Biomarkers for Early Detection, Prognosis, and Therapeutics of Esophageal Cancers
title_short Biomarkers for Early Detection, Prognosis, and Therapeutics of Esophageal Cancers
title_sort biomarkers for early detection, prognosis, and therapeutics of esophageal cancers
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9968115/
https://www.ncbi.nlm.nih.gov/pubmed/36834728
http://dx.doi.org/10.3390/ijms24043316
work_keys_str_mv AT raivikrant biomarkersforearlydetectionprognosisandtherapeuticsofesophagealcancers
AT abdojoe biomarkersforearlydetectionprognosisandtherapeuticsofesophagealcancers
AT agrawaldevendrak biomarkersforearlydetectionprognosisandtherapeuticsofesophagealcancers